Eyenovia (EYEN) Earns Buy Rating from Analysts at Roth Capital
Roth Capital assumed coverage on shares of Eyenovia (NASDAQ:EYEN) in a research report sent to investors on Tuesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $20.00 price target on the stock.
Shares of Eyenovia (EYEN) opened at $9.55 on Tuesday. The stock has a market capitalization of $94.90 and a price-to-earnings ratio of -22.74. Eyenovia has a 1-year low of $7.32 and a 1-year high of $10.74.
In other Eyenovia news, Director Fredric N. Eshelman bought 335,000 shares of Eyenovia stock in a transaction dated Monday, January 29th. The stock was bought at an average price of $10.00 per share, for a total transaction of $3,350,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Eyenovia Company Profile
Eyenovia, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing a pipeline of ophthalmology products utilizing its piezo-print technology to deliver micro-doses of active pharmaceutical ingredients (micro-therapeutics) to the eye. Its product candidates include MicroProst, MicroStat, MicroTears and MicroPine.
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.